Advanced Biomedical Research

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 3  |  Issue : 1  |  Page : 262-

The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial


Gita Faghihi1, Kioumars Jamshidi1, Nabet Tajmirriahi2, Bahareh Abtahi-Naeini1, Mohamadali Nilforoshzadeh1, Mohamadreza Radan3, Sayed Mohsen Hosseini1 
1 Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Dermatology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
3 Department of Dermatology Center, Noorand Ali Asghar Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Kioumars Jamshidi
Department of Dermatology, Al-Zahra Hospital, Soffeh Blvd, Isfahan University of Medical Sciences, Isfahan
Iran

Background: SAHA (Seborrhea, Acne, Hirsutism and Androgenetic Alopecia) syndrome is a dermatologic disorder, with variant response to treatment. Triad of cutaneous hyperandrogenism included nodulocystic or severe acne, female pattern hair loss and hirsutism. Aim: The aim of this study is to compare the effectiveness of isotretinoin and cyproterone compound in the treatment of nodulocystic acne, in patients with SAHA syndrome or triad of cutaneous hyperandrogenism. Materials and Methods: 30 female patients with SAHA syndrome were divided randomly into two groups. Group A was treated with cyproterone compound from day 5 of menstrual cycle onwards for 3 weeks and a week without it and group B received isotretinoin, with a dose of 0.75 mg/kg per day from the beginning of menses onwards for 4 months. The results were evaluated by a blind dermatologist using Acne Severity Index (ASI) score at baseline and monthly for 4 months. Results: Despite a continuous reduction in ASI score in both the groups, according to both physician (P = 0.63) and patient (P = 0.25) assessment, cyproterone compound was not statistically more effective than conventional treatment of nodulocystic acne at the end of the study. Side-effects were reported in patients in both groups, generally being mild and tolerable except in two subjects. Conclusion: This study indicates that cyproterone compound is not superior to isotretinoin in the treatment of nodulocystic acne in patient with SAHA syndrome or triad of cutaneous hyperandrogenism. Indeed, other studies are needed to evaluate the effect of cyproterone compound (regardless of androgen level) and isotretinoin in subjects with only nodulocystic acne.


How to cite this article:
Faghihi G, Jamshidi K, Tajmirriahi N, Abtahi-Naeini B, Nilforoshzadeh M, Radan M, Hosseini SM. The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial.Adv Biomed Res 2014;3:262-262


How to cite this URL:
Faghihi G, Jamshidi K, Tajmirriahi N, Abtahi-Naeini B, Nilforoshzadeh M, Radan M, Hosseini SM. The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial. Adv Biomed Res [serial online] 2014 [cited 2020 Aug 12 ];3:262-262
Available from: http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=262;epage=262;aulast=Faghihi;type=0